Correlation Between Teva Pharma and Avenue Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Teva Pharma and Avenue Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Teva Pharma and Avenue Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Teva Pharma Industries and Avenue Therapeutics, you can compare the effects of market volatilities on Teva Pharma and Avenue Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Teva Pharma with a short position of Avenue Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Teva Pharma and Avenue Therapeutics.

Diversification Opportunities for Teva Pharma and Avenue Therapeutics

-0.07
  Correlation Coefficient

Good diversification

The 3 months correlation between Teva and Avenue is -0.07. Overlapping area represents the amount of risk that can be diversified away by holding Teva Pharma Industries and Avenue Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Avenue Therapeutics and Teva Pharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Teva Pharma Industries are associated (or correlated) with Avenue Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Avenue Therapeutics has no effect on the direction of Teva Pharma i.e., Teva Pharma and Avenue Therapeutics go up and down completely randomly.

Pair Corralation between Teva Pharma and Avenue Therapeutics

Given the investment horizon of 90 days Teva Pharma Industries is expected to generate 0.85 times more return on investment than Avenue Therapeutics. However, Teva Pharma Industries is 1.18 times less risky than Avenue Therapeutics. It trades about 0.11 of its potential returns per unit of risk. Avenue Therapeutics is currently generating about -0.08 per unit of risk. If you would invest  1,772  in Teva Pharma Industries on September 21, 2024 and sell it today you would earn a total of  436.00  from holding Teva Pharma Industries or generate 24.6% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

Teva Pharma Industries  vs.  Avenue Therapeutics

 Performance 
       Timeline  
Teva Pharma Industries 

Risk-Adjusted Performance

8 of 100

 
Weak
 
Strong
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Teva Pharma Industries are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. Despite somewhat unfluctuating basic indicators, Teva Pharma sustained solid returns over the last few months and may actually be approaching a breakup point.
Avenue Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Avenue Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite inconsistent performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in January 2025. The recent confusion may also be a sign of long-lasting up-swing for the firm traders.

Teva Pharma and Avenue Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Teva Pharma and Avenue Therapeutics

The main advantage of trading using opposite Teva Pharma and Avenue Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Teva Pharma position performs unexpectedly, Avenue Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Avenue Therapeutics will offset losses from the drop in Avenue Therapeutics' long position.
The idea behind Teva Pharma Industries and Avenue Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..

Other Complementary Tools

Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance